PureTech Health (GB:PRTC) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PureTech Health is poised to present pivotal data on LYT-100, a promising treatment for idiopathic pulmonary fibrosis (IPF), at CHEST 2024 Annual Meeting in Boston. The company expects to unveil topline results from the Phase 2b ELEVATE IPF trial by year-end and aims to progress to a Phase 3 trial, potentially setting the stage for a new standard in IPF care. With LYT-100 designed to offer improved tolerability over existing treatments, PureTech is targeting a larger market of patients currently underserved due to side effects of current IPF medications.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
